Rheumatoid Arthritis | TreatmentTrends | EU5 | 2014

launch Related Market Assessment Reports

• Rheumatoid Arthritis – Landscape & Forecast – Disease Landscape & Forecast

  November 2023

  Although tumor necrosis factor-alpha (TNF-α) inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) patients refractory to conventional DMARD treatment (the first-…

• Rheumatoid Arthritis – Geographic Focus – China – Rheumatoid Arthritis – China In-Depth (China)

  October 2023

  Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that primarily affects the joints. China has the highest number of RA patients in the world, and disease management is…

• Rheumatoid Arthritis – Unmet Need – Detailed, Expanded Analysis: TNF-Alpha Refractory Rheumatoid Arthritis (US/EU)

  July 2023

  Rheumatoid arthritis (RA) patients who are refractory to one or more tumor necrosis factor-alpha (TNF-α) inhibitors are generally prescribed a non-TNF-targeted therapy (e.g., Bristol Myers Squibb…

• Rheumatoid Arthritis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

  May 2023

  The treatment of rheumatoid arthritis (RA) typically begins with cost-effective conventional DMARDs (cDMARDs), such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or…

• Rheumatoid Arthritic Pain – Epidemiology – Europe

  February 2023

  Clarivate Epidemiology’s coverage of rheumatoid arthritis (RA) pain comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…